Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD (continued)
Study
Description Intervention
Author:
Reaven et al.,
2009
Country:
US
Practice
setting:
Academic
Intervention
setting:
Clinic
Enrollment
period:
NR
Funding:
Organization for
Autism Research;
Doug Flutie
Foundation; US
DHHS
Administration on
Developmental
Disabilities
Author industry
relationship
disclosures:
NR
Intervention:
12 weekly 1.5 hour CBT
sessions targeting anxiety
reduction, including large
group time, separate
parent and child group
meetings, and parentchild
dyads
Assessment:
Two to three 2 hour
assessment sessions;
diagnostic and developmental
batteries (ADOS,
SCQ, WASI, K-SADS-PL,
SCARED) administered
by research team (clinical
psychologist with
extensive experience in
autism, graduate student,
postdoctoral fellow)
Groups:
G1: active treatment
G2: waitlist control
Provider:
Clinicians, parents
Measure of treatment
fidelity reported:
Inclusion/ Exclusion
Criteria/ Population
Inclusion criteria:
• Aged 7-14 years
• Diagnosis on the autism
spectrum as verified by
exceeding the criteria on
module III of the ADOS,
exceeding the cutoff on
the Social Communication
Questionnaire,
and receiving a current
clinical diagnosis of ASD
by a licensed clinical
psychologist with
extensive experience
with children with autism
• Overall IQ ≥ 70
• Verbally fluent as evidenced
by participation
in Module III of the
ADOS
• Significant anxiety
symptoms (parent report
of clinically significant
symptoms of a social
phobia, separation
anxiety, or generalized
anxiety on the Kiddie-
C-87
Baseline
Measures Outcomes
G3: NR
G1a: 6.80 ± 1.93
G2a: 6.50 ± 2.27
G3a: NR
G3s: 5.40 ± 1.95
G3d: 6.60 ± 1.67
ANOVA (only
groups G1 & G2,
trials 1-10):
G1/G2: P = NS
Improvement
across trials:
P < 0.001
Harms:
NR
Modifiers:
Condition-trial
interaction (G1
and G2 improve
across trials 1-4,
G3 no improvement):
P < 0.001
Condition-trial
interaction (G1a
and G2a improve
across trials 1-4,
G3a no improvement):
P < 0.001
WISC-IV VCI:
P < 0.001
Commonly
occurring
comorbidities:
SCARED score,
parent report, mean
± SD (range):
Total:
G1: 32.70 ± 12.21
(20-54)
G2: 29.35 ± 10.69
(7-51)
Panic symptoms:
G1: 4.40 ± 4.2
(0-15)
G2: 4.91 ± 4.55
(1-18)
Generalized anxiety:
G1: 9.94 ± 2.61
(5-13)
G2: 9.84 ± 3.82
(3-16)
Separation anxiety:
G1: 4.92 ± 3.87
(1-13)
G2: 5.13 ± 4.39
(0-16)
Social anxiety:
Commonly
occurring comorbidities:
SCARED, parent
report, mean ± SD
(range)
Total:
G1: 19.53 ± 8.82
(9-38)
G2: 27.33 ± 8.85
(9-52)
ANOVA: time (P =
0.01), treatment X
time interaction (P
= 0.01)
Panic symptoms:
G1: 2.34 ± 2.54
(0-7)
G2: 5.76 ± 4.44
(1-19)
Generalized
anxiety
G1: 6.20 ± 2.86
(2-12)
G2: 9.14 ± 3.16
(2-17)
Separation